KASTx Ventures celebrates the announcement today that Dr. Toshifumi Yokota has been selected for BioAlberta’s Scientific Achievement and Innovation Award. The award celebrates teams or individuals responsible for breakthrough innovations with commercial applications, and Dr. Yokota was one of two winners.  

Dr. Yokota was selected based on his seminal discoveries in antisense oligonucleotide (ASO) and gapmer therapies for muscular dystrophies like Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). KASTx founding partner Dr. Lawrence Korngut nominated Yokota for the award.  

“I have had the pleasure of working with Dr. Yokota in the neuromuscular and rare disease space, and I knew that he would be a perfect and important candidate to celebrate for this award,” Korngut said. “His research is truly revolutionizing future therapeutic development for rare diseases.” 

KASTx Ventures is teaming up with Dr. Yokota to launch a company dedicated to commercializing his therapies, developing groundbreaking therapies for rare diseases like DMD, FSHD, and other neuromuscular disorders. Subscribe to our newsletter to get future updates on the company’s development. 

Click here to read the full announcement by BioAlberta.